Merck & Co., Inc.(MRK)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

MRK $131.10
Snapshot
$131.10
After hours $130.41 -0.51%
52-Week Range
$76.66 – $131.74
YTD
+23.16%
IV Rank (30D)
23.82
Straddle Price
$9.27
P/C Vol Ratio
0.67
Market Cap
$322.3B
Fair Value
MODEL: SHORT

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.63%
Beta vs SPY1.00
Cost of Equity (CAPM)9.86% (VRP-adj)
WACC9.16%
Volatility Risk Premium+7.7pp (IV − HV30), ERP adj +23bps
Effective Tax Rate23.2%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon12 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$14.1B
Return on Equity (TTM)19.5%
Book / Price14.1%
Gross Margin (TTM)73.9%
FCF Margin (TTM)21.5%
Debt / Equity1.02
Quality Score4/6 — high quality (12y DCF)
Market-Implied Growth+10.7% (reverse-DCF on current price)
SMA 50$120.71 (Market Anchor value)
SMA 20 / Bollinger Mid$126.44
Bollinger Width / SMA206.1% (drives anchor stability)
Net Debt$41.3B
Market Cap$326B
Peers used for multiples: ABBV, AMGN, BMY, GILD, JNJ, LLY, PFE, UNH
Model Conviction
69%
20-Day Fair Value
≈ by Aug 24, 2026
$134.64
α +2.7% rank 12%
40-Day Fair Value
≈ by Sep 22, 2026
$123.80
α -5.5% rank 12%
60-Day Fair Value
≈ by Oct 21, 2026
$118.70
α -9.4% rank 12%
MethodImplied PriceWeightDetail
DCF $73.50 16%
DDM (Gordon) $50.71 13%
Peer P/E $100.10 7% median 27.3× · 8 peers
Peer EV/EBITDA $116.43 7% median 16.8× · 8 peers
Peer P/B $126.53 1% median 6.9× · 7 peers
Peer P/S $145.84 5% median 5.4× · 8 peers
Market Anchor (SMA50) $120.71 33% stability 100% (BB-width)
Options Expected (B-L 30d) $119.07 16% 39 strikes · skew +0.22
As of 2026-07-24 · updated
Info
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834)
Exchange
XNYS
Market Cap
$322.3B

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).

Summary
composite
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
MonthAvg ReturnYears of Data
Jan -0.85% 23
Feb -0.36% 23
Mar +0.51% 23
Apr +1.77% 23
May +0.64% 23
Jun +0.95% 23
Jul +0.18% 23
Aug +0.74% 22
Sep -2.36% 23
Oct -0.18% 23
Nov +1.67% 23
Dec +2.09% 23
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators
SMA 20: $126.72
SMA 50: $121.09
SMA 200: $110.49
Current: $131.07
EMA 12: $127.03
EMA 26: $124.90
MACD: 2.1353 | Signal: 0.2640
BULLISH
ADX (14): 17.71
RANGE
+DI: 32.03
−DI: 18.39
Momentum Oscillators
RSI (14): 61.85
NEUTRAL
Stoch %K: 82.15
Stoch %D: 67.09
Williams %R: -5.79
Volume & Volatility
BB Upper: $131.94
BB Lower: $121.50
NEUTRAL
OBV: -61,823,838
Vol SMA 20: 9,245,847
Vol ROC: -26.65%
ATR: $3.38
True Range: $1.47
HV 20: 32.6%
HV 30: 33.2%
HV 60: 31.0%

Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-07-26T00:00:00 – 2026-07-24T00:00:00
AI Analysis

Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

News
IBDT2·8d ago
Merck snagged the first-ever approval for a PCSK9 pill to lower LDL cholesterol, starting a new rivalry with injection-makers. The post Merck Snags A First-Of-Its-Kind Approval, And Shares Jump appeared first on Investor's Business Daily .
Earnings History
6 of 8 under expected move
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-07-30 Pre-Market 4.16% 9.75% 2.34x Exceeded
2024-10-31 Pre-Market 4.89% 2.25% 0.46x Within
2025-02-04 Pre-Market 5.01% 9.57% 1.91x Exceeded
2025-04-24 Pre-Market 6.64% 1.00% 0.15x Within
2025-07-29 Pre-Market 5.14% 0.92% 0.18x Within
2025-10-30 Pre-Market 4.41% 0.43% 0.10x Within
2026-02-03 Pre-Market 4.79% 1.93% 0.40x Within
2026-04-30 Pre-Market 4.58% 1.59% 0.35x Within
Options Activity
IV Rank (30D)
23.82
IV Rank (7D)
58.94
Avg IV
44.3%
Straddle (30D)
$9.27
Straddle (7D)
$3.96
P/C Volume
0.67
Spread Scanner GPU

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
pts EXTREME
ATM — / Wing —
30 DTE / 10d
pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
0.12
Correlation (SPY)
5.3%
0.00
Ann. Volatility
28.2%
SPY Volatility
12.7%

Low volatility - stock moves less than market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-06-30
Diluted shares outstanding: 2,497,500,000 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

3,893 filers1,902,062,667 shares$214.05B value76.16% of float
# Filer Shares Value % of Total % of Float Period
1 BlackRock, Inc. Custodian 225,830,330 $27.17B 12.69% 9.04% 2026-03-31
2 VANGUARD GROUP INC Custodian 254,322,763 $26.77B 12.51% 10.18% 2025-12-31
3 STATE STREET CORP 119,325,673 $14.45B 6.75% 4.78% 2026-03-31
4 WELLINGTON MANAGEMENT GROUP LLP Custodian 84,314,971 $10.14B 4.74% 3.38% 2026-03-31
5 GEODE CAPITAL MANAGEMENT, LLC Custodian 59,558,154 $7.14B 3.34% 2.38% 2026-03-31
6 JPMORGAN CHASE & CO Custodian 52,972,983 $6.26B 2.92% 2.12% 2026-03-31
7 CHARLES SCHWAB INVESTMENT MANAGEMENT INC 49,765,225 $5.99B 2.80% 1.99% 2026-03-31
8 FMR LLC Custodian 44,516,010 $5.35B 2.50% 1.78% 2026-03-31
9 MORGAN STANLEY Custodian 44,946,021 $4.73B 2.21% 1.80% 2025-12-31
10 BANK OF AMERICA CORP /DE/ Custodian 30,774,221 $3.70B 1.73% 1.23% 2026-03-31
11 NORTHERN TRUST CORP Custodian 27,090,023 $3.26B 1.52% 1.08% 2026-03-31
12 Fisher Asset Management, LLC 26,436,284 $3.18B 1.49% 1.06% 2026-03-31
13 UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME Custodian 20,414,819 $2.46B 1.15% 0.82% 2026-03-31
14 GOLDMAN SACHS GROUP INC Custodian 20,133,379 $2.42B 1.13% 0.81% 2026-03-31
15 Legal & General Group Plc Custodian 19,538,545 $2.35B 1.10% 0.78% 2026-03-31
16 Bank of New York Mellon Corp Custodian 18,713,363 $2.25B 1.05% 0.75% 2026-03-31
17 FRANKLIN RESOURCES INC Custodian 16,267,205 $1.96B 0.91% 0.65% 2026-03-31
18 DIMENSIONAL FUND ADVISORS LP Custodian 15,456,039 $1.86B 0.87% 0.62% 2026-03-31
19 UBS Group AG Custodian 13,933,630 $1.68B 0.78% 0.56% 2026-03-31
20 STATE FARM MUTUAL AUTOMOBILE INSURANCE CO 13,794,969 $1.66B 0.78% 0.55% 2026-03-31
21 Amundi Custodian 13,764,954 $1.66B 0.77% 0.55% 2026-03-31
22 ROYAL BANK OF CANADA Custodian 13,201,722 $1.59B 0.74% 0.53% 2026-03-31
23 DEUTSCHE BANK AG\ Custodian 12,540,774 $1.51B 0.70% 0.50% 2026-03-31
24 HARRIS ASSOCIATES L P 12,366,933 $1.49B 0.69% 0.50% 2026-03-31
25 WELLS FARGO & COMPANY/MN Custodian 11,446,845 $1.38B 0.64% 0.46% 2026-03-31
62 filers$3.51B notional
# Filer Notional Value % of Total Period
1 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $930.95M 26.49% 2026-03-31
2 CITADEL ADVISORS LLC Custodian $667.83M 19.00% 2026-03-31
3 JANE STREET GROUP, LLC Custodian $465.46M 13.24% 2026-03-31
4 JPMORGAN CHASE & CO Custodian $194.79M 5.54% 2026-03-31
5 TORONTO DOMINION BANK $116.08M 3.30% 2026-03-31
6 IMC-Chicago, LLC Custodian $109.61M 3.12% 2026-03-31
7 D. E. Shaw & Co., Inc. Custodian $104.44M 2.97% 2026-03-31
8 SIMPLEX TRADING, LLC Custodian $75.31M 2.14% 2026-03-31
9 WOLVERINE TRADING, LLC Custodian $66.05M 1.88% 2025-09-30
10 TUDOR INVESTMENT CORP ET AL $61.58M 1.75% 2026-03-31
11 Squarepoint Ops LLC $58.45M 1.66% 2026-03-31
12 WELLS FARGO & COMPANY/MN Custodian $58.11M 1.65% 2026-03-31
13 GOLDMAN SACHS GROUP INC Custodian $53.28M 1.52% 2026-03-31
14 BNP PARIBAS FINANCIAL MARKETS Custodian $49.57M 1.41% 2026-03-31
15 GROUP ONE TRADING LLC Custodian $47.38M 1.35% 2026-03-31
16 Alphadyne Asset Management LP $42.81M 1.22% 2026-03-31
17 MILLENNIUM MANAGEMENT LLC Custodian $38.28M 1.09% 2026-03-31
18 Qube Research & Technologies Ltd $37.59M 1.07% 2026-03-31
19 Man Group plc $34.93M 0.99% 2026-03-31
20 UBS Group AG Custodian $32.53M 0.93% 2026-03-31
21 Eisler Capital Management Ltd. $30.15M 0.86% 2025-09-30
22 CAPITAL FUND MANAGEMENT S.A. $28.87M 0.82% 2026-03-31
23 CITIGROUP INC Custodian $25.53M 0.73% 2026-03-31
24 Walleye Trading LLC $22.49M 0.64% 2026-03-31
25 Point72 Asset Management, L.P. $19.76M 0.56% 2026-03-31
64 filers$2.82B notional
# Filer Notional Value % of Total Period
1 CITADEL ADVISORS LLC Custodian $450.27M 15.94% 2026-03-31
2 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $386.66M 13.69% 2026-03-31
3 JANE STREET GROUP, LLC Custodian $280.61M 9.94% 2026-03-31
4 CITIGROUP INC Custodian $213.29M 7.55% 2026-03-31
5 MILLENNIUM MANAGEMENT LLC Custodian $187.24M 6.63% 2026-03-31
6 GOLDMAN SACHS GROUP INC Custodian $151.06M 5.35% 2026-03-31
7 BNP PARIBAS FINANCIAL MARKETS Custodian $104.51M 3.70% 2026-03-31
8 Hudson Bay Capital Management LP $96.23M 3.41% 2026-03-31
9 JPMORGAN CHASE & CO Custodian $91.02M 3.22% 2026-03-31
10 IMC-Chicago, LLC Custodian $89.32M 3.16% 2026-03-31
11 D. E. Shaw & Co., Inc. Custodian $78.39M 2.78% 2026-03-31
12 UBS Group AG Custodian $54.65M 1.94% 2026-03-31
13 Qube Research & Technologies Ltd $52.70M 1.87% 2026-03-31
14 Alphadyne Asset Management LP $50.94M 1.80% 2026-03-31
15 SIMPLEX TRADING, LLC Custodian $49.98M 1.77% 2026-03-31
16 CAPSTONE INVESTMENT ADVISORS, LLC $47.78M 1.69% 2026-03-31
17 Man Group plc $35.05M 1.24% 2026-03-31
18 Eisler Capital Management Ltd. $30.46M 1.08% 2025-09-30
19 WOLVERINE TRADING, LLC Custodian $30.06M 1.06% 2025-09-30
20 CREDIT AGRICOLE S A $29.47M 1.04% 2026-03-31
21 TUDOR INVESTMENT CORP ET AL $28.83M 1.02% 2026-03-31
22 CAPITAL FUND MANAGEMENT S.A. $28.36M 1.00% 2026-03-31
23 Centiva Capital, LP $24.06M 0.85% 2026-03-31
24 HSBC HOLDINGS PLC Custodian $22.71M 0.80% 2026-03-31
25 Allianz Asset Management GmbH $20.75M 0.73% 2026-03-31
Insider Activity
Latest: 2026-07-01
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-07-01 Surendralal Lanca Karsanbhai Director Award (A) EDGAR
2026-07-01 Mary Ellen Coe Director Award (A) EDGAR
2026-07-01 Christine E Seidman Director Award (A) EDGAR
2026-06-02 DOUGLAS M JR BAKER Director Award (A) EDGAR
2026-06-02 Pamela J. Craig Director Award (A) EDGAR
2026-06-02 THOMAS H GLOCER Director Award (A) EDGAR
2026-06-02 RISA J LAVIZZO-MOUREY Director Award (A) EDGAR
2026-06-02 Stephen Mayo Director Award (A) EDGAR
2026-06-02 Paul Rothman Director Award (A) EDGAR
2026-06-02 PATRICIA F RUSSO Director Award (A) EDGAR
2026-06-02 Christine E Seidman Director Award (A) EDGAR
2026-06-02 INGE G THULIN Director Award (A) EDGAR
2026-06-02 Mary Ellen Coe Director Award (A) EDGAR
2026-06-02 Surendralal Lanca Karsanbhai Director Award (A) EDGAR
2026-06-02 Kathy J Warden Director Award (A) EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
85 insiders · @ $131.07
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 KENNETH C FRAZIER Executive Chair 915,989 $120.06M -$455.27M 76 2022-11-08
2 Robert M Davis Chairman, CEO & President 450,350 $59.03M -$123.52M 30 2026-05-07
3 JUDY C LEWENT Exec.V.P.& C.F.O. 232,728 $30.50M -$10.26M 10 2007-08-09
4 ROGER M PERLMUTTER Exe V-P & Pres, MRL 215,059 $28.19M -$16.97M 14 2020-05-05
5 Adam H Schechter EVP & Pres-Global Human Health 200,540 $26.28M -$65.46M 50 2018-11-02
6 PETER S KIM Exe V-P & Pres, MRL 190,957 $25.03M -$19.11M 23 2013-02-27
7 Richard R. DeLuca EVP&Pres, Merck Animal Heallth 162,858 $21.35M -$64.44M 41 2026-05-07
8 Bruce N Kuhlik Exe V-P & Gen Counsel 150,432 $19.72M -$29.83M 33 2015-05-05
9 PETER N KELLOGG Exe V-P & CFO 149,553 $19.60M $502.4K 18 2014-02-26
10 RICHARD T CLARK Chairman 135,777 $17.80M -$2.14M 19 2011-03-01
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
Notice of Proposed Sale (Form 144)
Latest: 2026-02-13
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-02-13 144/A CHIRFI GUINDO Officer 20,000 $2.37M 2026-02-09 Morgan Stanley Smith Barney LLC … EDGAR
2026-02-10 DEAN LI Officer 10,235 $1.20M 2026-02-10 Morgan Stanley Smith Barney LLC … EDGAR
2026-02-09 JENNIFER ZACHARY Officer 121,573 $14.49M 2026-02-09 Morgan Stanley Smith Barney LLC … EDGAR
2026-02-09 CHIRFI GUINDO Officer 20,000 $2.37M 2026-02-09 Morgan Stanley Smith Barney LLC … EDGAR
2026-02-06 RICHARD ROBERT DELUCA JR. Officer 37,685 $4.56M 2026-02-06 Morgan Stanley Smith Barney LLC … EDGAR
2026-02-06 DAVID WILLIAMS Officer 5,000 $609.5K 2026-02-06 Morgan Stanley Smith Barney LLC … EDGAR
2026-02-06 JOHANNES JACOBUS OOSTHUIZEN Officer 15,000 $1.83M 2026-02-06 Morgan Stanley Smith Barney LLC … EDGAR
2026-02-05 CHIRFI GUINDO Officer 20,000 $2.44M 2026-02-05 Morgan Stanley Smith Barney LLC … EDGAR
2026-02-04 DALTON SMART Officer 6,400 $765.9K 2026-02-04 Morgan Stanley Smith Barney LLC … EDGAR
2026-02-04 ROBERT M. DAVIS Officer 47,434 $5.60M 2026-02-04 Morgan Stanley Smith Barney LLC … EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed.
Recent SEC Filings
Latest: 2026-05-28
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Accession Link
2026-05-28 0001104659-26-067509 EDGAR
2026-05-22 0001628280-26-037738 EDGAR
2026-04-30 0001104659-26-052081 EDGAR
2026-02-03 0001104659-26-009495 EDGAR
2025-12-04 0001628280-25-055388 EDGAR
2025-10-30 0001104659-25-103974 EDGAR
2025-09-09 0000310158-25-000047 EDGAR
2025-07-29 0001104659-25-071380 EDGAR
2025-05-29 0001104659-25-054131 EDGAR
2025-04-24 0001104659-25-038301 EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
2026-02-24 0000310158-26-000063 EDGAR
2025-02-25 0001628280-25-007732 EDGAR
2024-02-26 0001628280-24-006850 EDGAR
2023-02-24 0001628280-23-005061 EDGAR
2022-02-25 0000310158-22-000003 EDGAR
2021-02-25 0000310158-21-000004 EDGAR
2020-02-26 0000310158-20-000005 EDGAR
2019-02-27 0000310158-19-000014 EDGAR
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-05-04 0001628280-26-029802 EDGAR
2025-11-05 0000310158-25-000059 EDGAR
2025-08-05 0000310158-25-000014 EDGAR
2025-05-02 0001628280-25-021834 EDGAR
2024-11-06 0001628280-24-045689 EDGAR
2024-08-05 0001628280-24-034715 EDGAR
2024-05-03 0001628280-24-020283 EDGAR
2023-11-03 0001628280-23-036717 EDGAR
2023-08-07 0001628280-23-027770 EDGAR
2023-05-05 0001628280-23-015990 EDGAR
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/E Ratio36.8
P/B Ratio7.0
P/S Ratio4.9
EV/EBITDA19.0
TTM Revenue$65.8B
TTM Net Income$8.9B
TTM EPS$3.56
ROE19.5%
Dividend Yield2.55%
Debt/Equity1.07